User profiles for R. O. Bagge
 | Roger Olofsson BaggeProfessor, Gothenburg University Verified email at gu.se Cited by 3474 |
Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches
…, S Bae, R Bagabas, RO Bagge… - Journal of …, 2024 - Wiley Online Library
Extracellular vesicles (EVs), through their complex cargo, can reflect the state of their cell of
origin and change the functions and phenotypes of other cells. These features indicate …
origin and change the functions and phenotypes of other cells. These features indicate …
[HTML][HTML] ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
Highlights • A melanoma consensus conference, organised by the ESMO Guidelines
Committee, was attended by 32 experts from 14 countries • The experts compiled …
Committee, was attended by 32 experts from 14 countries • The experts compiled …
[HTML][HTML] Characterization of surface markers on extracellular vesicles isolated from lymphatic exudate from patients with breast cancer
…, HI Pétursson, J Johansson, C Lässer, RO Bagge - BMC cancer, 2022 - Springer
Background Breast cancer is the most common cancer, and the leading cause of cancer-related
deaths, among females world-wide. Recent research suggests that extracellular …
deaths, among females world-wide. Recent research suggests that extracellular …
[HTML][HTML] ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee
Highlights • A melanoma consensus conference, organised by the ESMO Guidelines
Committee, was attended by 32 experts from 14 countries • The experts compiled …
Committee, was attended by 32 experts from 14 countries • The experts compiled …
HER2 CAR-T cells eradicate uveal melanoma and T-cell therapy–resistant human melanoma in IL2 transgenic NOD/SCID IL2 receptor knockout mice
…, MF Lindberg, H Jespersen, S Alsén, RO Bagge… - Cancer Research, 2019 - AACR
… RO Bagge has received speakers bureau honoraria from Roche and is a consultant/advisory
board member for MSD, BMS, and Amgen. L. Ny reports receiving other commercial …
board member for MSD, BMS, and Amgen. L. Ny reports receiving other commercial …
[HTML][HTML] Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions
The development of novel therapies against melanoma would benefit from individualized
tumor models to ensure the rapid and accurate identification of biomarkers of therapy response…
tumor models to ensure the rapid and accurate identification of biomarkers of therapy response…
[HTML][HTML] Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is …
Background In patients with cutaneous melanoma, sentinel lymph node biopsy (SLNB) serves
as an important technique to asses disease stage and to guide adjuvant systemic therapy. …
as an important technique to asses disease stage and to guide adjuvant systemic therapy. …
[HTML][HTML] Supporting clinical decision making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse models
Background The mouse strains usually used to generate patient-derived xenografts (PDXs)
are immunocompromised, rendering them unsuitable for immunotherapy studies. Here we …
are immunocompromised, rendering them unsuitable for immunotherapy studies. Here we …
[HTML][HTML] The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases–A multicenter cohort study
… We demonstrate a five-year OS of 63%, and in comparison, 44% for patients treated with ILI
as shown by Kroon et al.; 26% for patients treated with ILP as shown by Olofsson Bagge et al.…
as shown by Kroon et al.; 26% for patients treated with ILP as shown by Olofsson Bagge et al.…
[HTML][HTML] Adjuvant chemotherapy and survival in women aged 70 years and older with triple-negative breast cancer: a Swedish population-based propensity score …
…, B Linderholm, RA Audisio, RO Bagge - The Lancet Healthy …, 2020 - thelancet.com
Background Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer
associated with poor survival, in which adjuvant systemic treatments are limited to …
associated with poor survival, in which adjuvant systemic treatments are limited to …